Commenting on the results, Peter Gray, CEO at ICON, said “Our relationships with sites are the lynchpin of everything that we do and we are delighted that the excellent work by our site monitoring and project management staff worldwide is being recognised. We place a lot of emphasis on training, managing and supporting our staff to respond to the needs of our investigative sites and we remain committed to developing open and transparent relationships with investigators.”
The CenterWatch survey, which was conducted online between February and March, 2011, measured the responses from 1,205 principal investigators, sub-investigators and study coordinators from sites worldwide, with more than 75% of respondents from North America and Europe. Sites were requested to rate the CROs they had worked with in the past two years on 29 relationship attributes and to provide feedback on the importance of these attributes when conducting their clinical trials.
About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has almost 7,800 employees, operating from 77 locations in 39 countries. www.iconplc.com
For more information please contact:
Genevieve Tuck
Weber Shandwick
Gtuck@webershandwick.com
+44 (0) 2070 670 655
